Cite
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
MLA
Fujita, A., et al. “Phase II Study of Cisplatin, Ifosfamide, and Irinotecan with RhG-CSF Support in Patients with Stage IIIb and IV Non-Small-Cell Lung Cancer.” British Journal of Cancer, vol. 89, no. 6, Sept. 2003, pp. 1008–12. EBSCOhost, https://doi.org/10.1038/sj.bjc.6601230.
APA
Fujita, A., Ohkubo, T., Hoshino, H., Takabatake, H., Tagaki, S., Sekine, K., & Abe, S. (2003). Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer. British Journal of Cancer, 89(6), 1008–1012. https://doi.org/10.1038/sj.bjc.6601230
Chicago
Fujita, A., T. Ohkubo, H. Hoshino, H. Takabatake, S. Tagaki, K. Sekine, and S. Abe. 2003. “Phase II Study of Cisplatin, Ifosfamide, and Irinotecan with RhG-CSF Support in Patients with Stage IIIb and IV Non-Small-Cell Lung Cancer.” British Journal of Cancer 89 (6): 1008–12. doi:10.1038/sj.bjc.6601230.